EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas

Background: Anti-EGFR antibody therapy is still one of the clinical choices in head and neck squamous cell carcinoma (HNSCC) patients, but the emergence of cetuximab resistance questioned its effectiveness and reduced its applicability. Although several possible reasons of resistance against the ant...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Pathol Oncol Res
Autores principales: Nelhűbel, Györgyi A., Cserepes, Mihály, Szabó, Balázs, Türk, Dóra, Kárpáti, Adél, Kenessey, István, Rásó, Erzsébet, Barbai, Tamás, Hegedűs, Zita, László, Viktória, Szokol, Bálint, Dobos, Judit, Őrfi, László, Tóvári, József
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2021
Materias:
Society Journal Archive
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262169/
https://ncbi.nlm.nih.gov/pubmed/34257586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/pore.2021.620256
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares